Merck KGaA has agreed to pay $780 million in cash for contract manufacturer Exelead, a specialist in the lipid nanoparticles needed for messenger RNA vaccines.
To read the entire story, you must be logged in.
Please log in now or register with us.
Intelligence for the Dealmaking Community since 1965
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
